The frenzy of artificial intelligence continues to soar. Recently, U.S. stock AI advertising marketing leader $Applovin (APP.US)$ have attracted global attention, with a stock price increase of over 850% since the beginning of the year, a market cap exceeding $127 billion, repeatedly hitting historic highs, and continuing the AI myth.
Read more: Why Are These AI Stocks Seeing Even Bigger Surges Than Nvidia This Year?
Citi has significantly increased its pric...

Good morning, traders. Happy Friday, it's nearly afternoon and a tropical storm is coming to Jersey city. The market is turbulent and trying to not fall after the S&P 500 hit its best day for the year on Thursday. Monday was the worst trading day for the S&P 500 in two years.
My name is Kevin Travers, here are moovin' stonks.
Eli Lilly $Eli Lilly and Co (LLY.US)$ climbed a further 7% Friday after a Thursday Q2 earnings beat, boo...

$Lyft Inc (LYFT.US)$ This is really garbage, getting lower as you go.

by Luzi Ann Santos | moomoo News
Magnificent Seven stocks dragged the rest of the stock market lower amid speculation investors are rotating out of this year's biggest gainers and rolling into equities whose strong fundamentals have been overshadowed by the artificial intelligence (AI) frenzy.
The $S&P 500 Index (.SPX.US)$ fell 2.3% to close at 5,427.13, while the $Nasdaq Composite Index (.IXIC.US)$ lost 3.6% to 5,427.13. The two...

See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...